Clinical Trial Detail

NCT ID NCT01946789
Title A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Altor Bioscience Corporation
Indications

head and neck squamous cell carcinoma

lung non-small cell carcinoma

melanoma

renal cell carcinoma

Therapies

ALT-803

Age Groups: adult

Additional content available in CKB BOOST